Abby Reinhard, Assistant Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2021. Email her at firstname.lastname@example.org
Higher-Dose Antiseizure Medications, Early Therapeutic Monitoring Necessary for Pregnant Women With EpilepsyMarch 10th 2022
The study had a goal to provide a personalized treatment approach, including ASM dosage changes to prevent seizure worsening and optimizing the balance of outcomes for mothers and children.
Geographic Gaps, Therapist Availability Significantly Associated With Poststroke Rehabilitation Care UtilizationMarch 9th 2022
The cohort study was conducted in Taiwan, with investigators also observing changes over time in the influence of sex, stroke type, and copayment exemption type of rehabilitation utilization.
Discussing the Need for Genetic Testing and Counseling in Parkinson DiseaseMarch 7th 2022
With the Parkinson’s Foundation recently being granted Joint Accreditation and announcing a new and free CME course, James Beck, PhD, senior vice president and chief scientific officer of the organization, commented on the pivotal role genetic testing can play.
MS Relapses, Health Care Utilization Greatest Among COVID-19 Vaccinated Patients Treated With Ocrelizumab, FingolimodMarch 7th 2022
Previously reported data show patients with multiple sclerosis treated with anti-CD20s have reduced response to COVID-19 vaccines, but there has been limited research on MS outcomes among vaccinated patients.
Rare Disease Day: Updates on Rare Neurological DiseasesFebruary 28th 2022
In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a wide range of rare neurological diseases, including Kleine-Levin syndrome, amyotrophic lateral sclerosis, cerebral palsy, Lennox-Gastaut syndrome, and more.
Cortical Lesion Burden Associated With Disability Worsening, Transition to Progressive Multiple SclerosisFebruary 27th 2022
Three-year follow-up data presented at the ACTRIMS Forum 2022 suggest cortical lesion burden, particularly subpial lesions, is the primary driver of worsening disability and conversion to secondary progressive MS.